Advertisement
Screener

NEUROCRINE BIOSCIENCES INC (NBIX) Increase (Decrease) in Inventories

2.8 / 5 stars · 68/120 Roast Me

NEUROCRINE BIOSCIENCES INC Increase (Decrease) in Inventories

NEUROCRINE BIOSCIENCES INC (NBIX) reported Increase (Decrease) in Inventories of $2.20 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-31.

Financial Statements › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInInventories · last filed 2026-07-31

  • NEUROCRINE BIOSCIENCES INC increase (decrease) in inventories for the quarter ending 2026-06-30 was $6.50M.
  • NEUROCRINE BIOSCIENCES INC increase (decrease) in inventories for the quarter ending 2026-03-31 was -$4.30M, a 352.94% decline year-over-year.
  • NEUROCRINE BIOSCIENCES INC increase (decrease) in inventories for the quarter ending 2025-12-31 was $3.40M, a 70.69% decline year-over-year.
  • NEUROCRINE BIOSCIENCES INC increase (decrease) in inventories for the quarter ending 2025-09-30 was $12.30M, a 272.73% increase year-over-year.
  • NEUROCRINE BIOSCIENCES INC increase (decrease) in inventories for fiscal 2025 was $15.30M, a 19.90% decline from fiscal 2024.
  • NEUROCRINE BIOSCIENCES INC increase (decrease) in inventories for fiscal 2024 was $19.10M.
  • NEUROCRINE BIOSCIENCES INC increase (decrease) in inventories for fiscal 2023 was -$5.40M, a 307.69% decline from fiscal 2022.
  • NEUROCRINE BIOSCIENCES INC increase (decrease) in inventories for fiscal 2022 was $2.60M, a 4.00% increase from fiscal 2021.
Period endIncrease (Decrease) in Inventories 3 monthIncrease (Decrease) in Inventories 3 month as first filedIncrease (Decrease) in Inventories 6 monthIncrease (Decrease) in Inventories 6 month as first filedIncrease (Decrease) in Inventories 9 monthIncrease (Decrease) in Inventories 9 month as first filedIncrease (Decrease) in Inventories 12 monthIncrease (Decrease) in Inventories 12 month as first filed
2026-06-30$6.50M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-31
$2.20M
10-Q · filed 2026-07-31
$5.60M
derived: sum of 3 quarters · filed 2026-07-31
$17.90M
derived: sum of 4 quarters · filed 2026-07-31
2026-03-31-$4.30M
10-Q · filed 2026-05-05
-$900.00K
derived: sum of 2 quarters · filed 2026-05-05
$11.40M
derived: sum of 3 quarters · filed 2026-05-05
$9.30M
derived: sum of 4 quarters · filed 2026-07-31
2025-12-31$3.40M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11
$15.70M
derived: sum of 2 quarters · filed 2026-02-11
$13.60M
derived: sum of 3 quarters · filed 2026-07-31
$15.30M
10-K · filed 2026-02-11
2025-09-30$12.30M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28
$10.20M
derived: sum of 2 quarters · filed 2026-07-31
$11.90M
10-Q · filed 2025-10-28
$23.50M
derived: sum of 4 quarters · filed 2026-07-31
2025-06-30-$2.10M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-31
-$400.00K
10-Q · filed 2026-07-31
$11.20M
derived: sum of 3 quarters · filed 2026-07-31
$14.50M
derived: sum of 4 quarters · filed 2026-07-31
2025-03-31$1.70M
10-Q · filed 2026-05-05
$13.30M
derived: sum of 2 quarters · filed 2026-05-05
$16.60M
derived: sum of 3 quarters · filed 2026-05-05
$21.90M
derived: sum of 4 quarters · filed 2026-05-05
2024-12-31$11.60M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11
$14.90M
derived: sum of 2 quarters · filed 2026-02-11
$20.20M
derived: sum of 3 quarters · filed 2026-02-11
$19.10M
10-K · filed 2026-02-11
2024-09-30$3.30M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28
$8.60M
derived: sum of 2 quarters · filed 2025-10-28
$7.50M
10-Q · filed 2025-10-28
$8.40M
derived: sum of 4 quarters · filed 2026-02-11
2024-06-30$5.30M
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-30
$4.20M
10-Q · filed 2025-07-30
$5.10M
derived: sum of 3 quarters · filed 2026-02-11
$2.20M
derived: sum of 4 quarters · filed 2026-02-11
2024-03-31-$1.10M
10-Q · filed 2025-05-05
-$200.00K
derived: sum of 2 quarters · filed 2026-02-11
-$3.10M
derived: sum of 3 quarters · filed 2026-02-11
-$4.70M
derived: sum of 4 quarters · filed 2026-02-11
2023-12-31$900.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11
-$2.00M
derived: sum of 2 quarters · filed 2026-02-11
-$3.60M
derived: sum of 3 quarters · filed 2026-02-11
-$5.40M
10-K · filed 2026-02-11
2023-09-30-$2.90M
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-30
-$4.50M
derived: sum of 2 quarters · filed 2024-10-30
-$6.30M
10-Q · filed 2024-10-30
-$10.20M
derived: sum of 4 quarters · filed 2025-02-10
2023-06-30-$1.60M
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01
-$3.40M
10-Q · filed 2024-08-01
-$7.30M
derived: sum of 3 quarters · filed 2025-02-10
$400.00K
derived: sum of 4 quarters · filed 2025-02-10
2023-03-31-$1.80M
10-Q · filed 2024-05-01
-$5.70M
derived: sum of 2 quarters · filed 2025-02-10
$2.00M
derived: sum of 3 quarters · filed 2025-02-10
$2.30M
derived: sum of 4 quarters · filed 2025-02-10
2022-12-31-$3.90M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-10
$3.80M
derived: sum of 2 quarters · filed 2025-02-10
$4.10M
derived: sum of 3 quarters · filed 2025-02-10
$2.60M
10-K · filed 2025-02-10
2022-09-30$7.70M
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-31
$8.00M
derived: sum of 2 quarters · filed 2023-10-31
$6.50M
10-Q · filed 2023-10-31
$11.50M
derived: sum of 4 quarters · filed 2024-02-09
2022-06-30$300.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-01
-$1.20M
10-Q · filed 2023-08-01
$3.80M
derived: sum of 3 quarters · filed 2024-02-09
$1.00M
derived: sum of 4 quarters · filed 2024-02-09
2022-03-31-$1.50M
10-Q · filed 2023-05-03
$3.50M
derived: sum of 2 quarters · filed 2024-02-09
$700.00K
derived: sum of 3 quarters · filed 2024-02-09
-$1.10M
derived: sum of 4 quarters · filed 2024-02-09
2021-12-31$5.00M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-09
$2.20M
derived: sum of 2 quarters · filed 2024-02-09
$400.00K
derived: sum of 3 quarters · filed 2024-02-09
$2.50M
10-K · filed 2024-02-09
2021-09-30-$2.80M
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-01
-$4.60M
derived: sum of 2 quarters · filed 2022-11-01
-$2.50M
10-Q · filed 2022-11-01
$4.80M
derived: sum of 4 quarters · filed 2023-02-09
2021-06-30-$1.80M
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04
$300.00K
10-Q · filed 2022-08-04
$7.60M
derived: sum of 3 quarters · filed 2023-02-09
$6.30M
derived: sum of 4 quarters · filed 2023-02-09
2021-03-31$2.10M
10-Q · filed 2022-05-04
$9.40M
derived: sum of 2 quarters · filed 2023-02-09
$8.10M
derived: sum of 3 quarters · filed 2023-02-09
$8.90M
derived: sum of 4 quarters · filed 2023-02-09
2020-12-31$7.30M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-09
$6.00M
derived: sum of 2 quarters · filed 2023-02-09
$6.80M
derived: sum of 3 quarters · filed 2023-02-09
$10.70M
10-K · filed 2023-02-09
2020-09-30-$1.30M
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-01
-$500.00K
derived: sum of 2 quarters · filed 2021-11-01
$3.40M
10-Q · filed 2021-11-01
$9.90M
derived: sum of 4 quarters · filed 2022-02-11
2020-06-30$800.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-03
$4.70M
10-Q · filed 2021-08-03
$11.20M
derived: sum of 3 quarters · filed 2022-02-11
$9.90M
derived: sum of 4 quarters · filed 2022-02-11
2020-03-31$3.90M
10-Q · filed 2021-05-05
$10.40M
derived: sum of 2 quarters · filed 2022-02-11
$9.10M
derived: sum of 3 quarters · filed 2022-02-11
$8.50M
derived: sum of 4 quarters · filed 2022-02-11
2019-12-31$6.50M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-11
$5.20M
derived: sum of 2 quarters · filed 2022-02-11
$4.60M
derived: sum of 3 quarters · filed 2022-02-11
$6.40M
10-K · filed 2022-02-11
$6.42M
10-K · filed 2020-02-07
2019-09-30-$1.30M
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09
-$1.90M
derived: sum of 2 quarters · filed 2020-11-09
-$100.00K
10-Q · filed 2020-11-09
-$66.00K
10-Q · filed 2019-11-04
-$507.00K
derived: sum of 4 quarters · filed 2021-02-05
2019-06-30-$600.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-03
$1.20M
10-Q · filed 2020-08-03
$1.15M
10-Q · filed 2019-07-29
$793.00K
derived: sum of 3 quarters · filed 2021-02-05
$1.43M
derived: sum of 4 quarters · filed 2021-02-05
2019-03-31$1.80M
10-Q · filed 2020-05-06
$1.75M
10-Q · filed 2019-04-29
$1.39M
derived: sum of 2 quarters · filed 2021-02-05
$2.03M
derived: sum of 3 quarters · filed 2021-02-05
$4.99M
derived: sum of 4 quarters · filed 2021-02-05
2018-12-31-$407.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-05
$229.00K
derived: sum of 2 quarters · filed 2021-02-05
$3.19M
derived: sum of 3 quarters · filed 2021-02-05
$3.50M
10-K · filed 2021-02-05
$3.52M
10-K · filed 2019-02-08
2018-09-30$636.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-04
$3.60M
derived: sum of 2 quarters · filed 2019-11-04
$3.91M
10-Q · filed 2019-11-04
$4.69M
derived: sum of 4 quarters · filed 2020-02-07
2018-06-30$2.96M
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-29
$3.27M
10-Q · filed 2019-07-29
$4.05M
derived: sum of 3 quarters · filed 2020-02-07
$4.17M
derived: sum of 4 quarters · filed 2020-02-07
2018-03-31$309.00K
10-Q · filed 2019-04-29
$1.09M
derived: sum of 2 quarters · filed 2020-02-07
$1.21M
derived: sum of 3 quarters · filed 2020-02-07
2017-12-31$782.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-07
$896.00K
derived: sum of 2 quarters · filed 2020-02-07
$1.02M
10-K · filed 2020-02-07
2017-09-30$114.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-05
$242.00K
10-Q · filed 2018-11-05
2017-06-30$128.00K
10-Q · filed 2018-07-31
2016-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-08
$0.00
derived: sum of 2 quarters · filed 2019-02-08
$0.00
10-K · filed 2019-02-08
2016-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-01
$0.00
10-Q · filed 2017-11-01
2016-06-30$0.00
10-Q · filed 2017-08-03
2015-12-31$0.00
10-K · filed 2018-02-13

Similar stocks

Stock NameCountryMarket CapPE Ratio
EXELIXIS, INC. (EXEL)United States$14.358B16.15
HALOZYME THERAPEUTICS, INC. (HALO)United States$13.083B21.59
Twist Bioscience Corp (TWST)United States$11.540B-47.21
BIO-TECHNE Corp (TECH)United States$11.379B74.68
REPLIGEN CORP (RGEN)United States$10.755B185.31
Krystal Biotech, Inc. (KRYS)United States$10.210B45.56
Kymera Therapeutics, Inc. (KYMR)United States$9.631B-31.69
ImmunityBio, Inc. (IBRX)United States$9.157B-9.29
Vaxcyte, Inc. (PCVX)United States$8.466B-7.91
Immunovant, Inc. (IMVT)United States$7.028B-14.78